Senzime Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
58
- Stock Symbol
-
SEZI
- Investments
-
3
- Share Price
-
$0.50
- (As of Friday Closing)
Senzime General Information
Description
Senzime AB is a medical device company providing patient monitoring systems. Its portfolio comprises systems for patient monitoring of neuromuscular function and breathing, typically during and after surgery, and for the intensive care sector. TetraGraph is a system based on EMG technology for neuromuscular monitoring during surgical procedures. ExSpiron 2Xi is a non-invasive monitoring system of respiratory volume and minute ventilation used for in and out patient care. The company operates in Sweden, Germany and the USA. It derives revenue through sales of monitors and associated disposable sensors to hospitals and clinics.
Contact Information
Website
www.senzime.comCorporate Office
- Verkstadsgatan 8
- Hus 1
- 753 23 Uppsala
- Sweden
Corporate Office
- Verkstadsgatan 8
- Hus 1
- 753 23 Uppsala
- Sweden
Senzime Timeline
Senzime Stock Performance
As of 16-May-2025, Senzime’s stock price is $0.50. Its current market cap is $67M with 133M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.50 | $0.50 | $0.36 - $0.92 | $67M | 133M | 216K | -$0.09 |
Senzime Financials Summary
As of 31-Mar-2025, Senzime has a trailing 12-month revenue of $6.56M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 55,571 | 63,312 | 83,696 | 67,791 |
| Revenue | 6,558 | 5,529 | 3,364 | 1,383 |
| EBITDA | (8,896) | (9,253) | (10,997) | (11,669) |
| Net Income | (11,778) | (11,226) | (12,621) | (13,081) |
| Total Assets | 37,882 | 38,643 | 43,380 | 30,932 |
| Total Debt | 2,138 | 2,054 | 1,147 | 1,250 |
Senzime Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Senzime Comparisons
Industry
Financing
Details
Senzime Competitors (15)
One of Senzime’s 15 competitors is Philips, a Corporation company based in Amsterdam, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Philips | Corporation | Amsterdam, Netherlands | ||||
| IDMed | Formerly Accelerator/Incubator backed | Marseille, France | ||||
| Abbott | Corporation | Abbot Park, IL | ||||
| GE HealthCare Technologies | Corporation | Chicago, IL | ||||
| Medtronic | Corporation | Minneapolis, MN |
Senzime Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Senzime Patents
Senzime Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3764873-A1 | Anesthetizing monitoring system, unit and method therefore | Active | 16-Mar-2018 | ||
| EP-3764894-A1 | Anesthetizing monitoring system, unit and method therefore | Inactive | 16-Mar-2018 | ||
| US-20210015403-A1 | Anesthetizing monitoring system, unit and method therefore | Inactive | 16-Mar-2018 | ||
| US-20210007661-A1 | Anesthetizing monitoring system, unit and method therefore | Pending | 16-Mar-2018 | ||
| ES-2980634-T3 | Anesthesia monitoring system, corresponding unit and method | Active | 16-Mar-2018 | A61B5/4821 |
Senzime Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Senzime Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Senzime Acquisitions (3)
Senzime’s most recent deal was a Merger/Acquisition with Respiratory Motion for . The deal was made on 01-Jul-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Respiratory Motion | 01-Jul-2022 | Merger/Acquisition | Monitoring Equipment | ||
| Acacia Designs | 03-May-2016 | Merger/Acquisition | Monitoring Equipment | ||
| MD Biomedical | 21-Apr-2015 | Merger/Acquisition | Other Healthcare Services |
Senzime ESG
Risk Overview
Risk Rating
Updated April, 21, 2023
18.2 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Technology Hardware
Industry
of 615
Rank
Percentile
Electronics Equipment
Subindustry
of 126
Rank
Percentile
Senzime FAQs
-
When was Senzime founded?
Senzime was founded in 1999.
-
Where is Senzime headquartered?
Senzime is headquartered in Uppsala, Sweden.
-
What is the size of Senzime?
Senzime has 58 total employees.
-
What industry is Senzime in?
Senzime’s primary industry is Monitoring Equipment.
-
Is Senzime a private or public company?
Senzime is a Public company.
-
What is Senzime’s stock symbol?
The ticker symbol for Senzime is SEZI.
-
What is the current stock price of Senzime?
As of 16-May-2025 the stock price of Senzime is $0.50.
-
What is the current market cap of Senzime?
The current market capitalization of Senzime is $67M.
-
What is Senzime’s current revenue?
The trailing twelve month revenue for Senzime is $6.56M.
-
Who are Senzime’s competitors?
Philips, IDMed, Abbott, GE HealthCare Technologies, and Medtronic are some of the 15 competitors of Senzime.
-
What is Senzime’s annual earnings per share (EPS)?
Senzime’s EPS for 12 months was -$0.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
